Enanta Pharmaceuticals Inc.

10/26/2026 | Press release | Distributed by Public on 10/26/2026 05:03

Enanta Pharmaceuticals Announces First Patient Dosed in the RESOLVE Phase 2b/3 Study of Zelicapavir, a Potential First-in-Disease Treatment for Respiratory Syncytial Virus (RSV)

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.
Enanta Pharmaceuticals Inc. published this content on October 26, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on October 26, 2026 at 11:10 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]